

JOHNSON & JOHNSON REPORTS 2021 FIRST-QUARTER RESULTS:

- **2021 First Quarter Sales of \$22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%***
- **2021 First Quarter EPS of \$2.32 increased 6.9%; adjusted EPS of \$2.59 increased 12.6%***
- **Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint**

New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere.”

OVERALL FINANCIAL RESULTS:

FIRST QUARTER			
(\$ in Millions, except EPS)	2021	2020	% Change
Reported Sales	\$ 22,321	\$ 20,691	7.9%
Net Earnings	6,197	5,796	6.9
EPS (diluted)	\$ 2.32	\$ 2.17	6.9%
Non-GAAP*			
FIRST QUARTER			
(\$ in Millions, except EPS)	2021	2020	% Change
Operational Sales^{1,2}			5.5%
Adjusted Operational Sales^{1,3}			6.0
Adjusted Net Earnings^{1,4}	6,924	6,154	12.5
Adjusted EPS (diluted)^{1,4}	\$ 2.59	\$ 2.30	12.6%

¹ [Non-GAAP financial measure](#); refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

⁴ Excludes intangible amortization expense and special items

REGIONAL SALES RESULTS:

(\$ in Millions)	FIRST QUARTER		% Change			
	2021	2020	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
U.S.	\$ 11,111	\$ 10,699	3.9%	3.9	-	3.9
International	11,210	9,992	12.2	7.3	4.9	8.2
Worldwide	\$ 22,321	\$ 20,691	7.9%	5.5	2.4	6.0

¹ [Non-GAAP financial measure](#); refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

SEGMENT SALES RESULTS:

(\$ in Millions)	FIRST QUARTER		% Change			
	2021	2020	Reported	Operational ^{1,2}	Currency	Adjusted Operational ^{1,3}
Consumer Health	\$ 3,543	\$ 3,625	(2.3)%	(3.3)	1.0	(2.9)
Pharmaceutical	12,199	11,134	9.6	7.1	2.5	7.4
Medical Devices	6,579	5,932	10.9	8.0	2.9	8.8
Worldwide	\$ 22,321	\$ 20,691	7.9%	5.5	2.4	6.0

¹ [Non-GAAP financial measure](#); refer to reconciliations of non-GAAP financial measures included in accompanying schedules

² Excludes the impact of translational currency

³ Excludes the net impact of acquisitions and divestitures and translational currency

Note: values may have been rounded

First-Quarter 2021 SEGMENT COMMENTARY:

Consumer Health

Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the-counter products. Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.

Pharmaceutical

Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset

by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.

Medical Devices

Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:

The information contained in this section should be read in conjunction with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company’s website at [news releases](#).

Regulatory Decisions	PONVORY (ponesimod) approved by U.S. FDA, an oral treatment for adults with relapsing multiple sclerosis proven superior to (teriflunomide) in reducing annual relapses and brain lesions	(press release)
	Johnson & Johnson Single-Shot COVID-19 Vaccine granted conditional marketing authorization by European Commission	(press release)
	Johnson & Johnson Single-Shot COVID-19 Vaccine granted emergency use listing by the World Health Organization	(press release)
	Johnson & Johnson COVID-19 Vaccine authorized by U.S. FDA for emergency use	(press release)
	SPRAVATO (Esketamine Nasal Spray) authorized in Europe for the rapid reduction of depressive symptoms in a psychiatric emergency for patients with major depressive disorder	(press release)
	MONOFOCAL INTRAOCULAR LENS - TECNIS EYHANCE AND TECNIS EYHANCE TORIC II IOLS - receives FDA approval for a next generation treatment for cataract patients	(press release)
Regulatory Submission	Submission of supplemental new drug application to U.S. FDA by ViiV Healthcare for expanded use of CABENUVA (rilpivirine and cabotegravir) as an HIV treatment for use every two months	(press release)
Other	Janssen provides update on Phase 3 ACIS Study in patients with metastatic castration-resistant prostate cancer treated with ERLEADA (apalutamide) and ZYTIGA (abiraterone acetate) plus prednisone combination ¹	(press release)
	Johnson & Johnson announces advance purchase agreement with the African Vaccine Acquisition Trust for the Company’s COVID-19 vaccine candidate	(press release)
	PONVORY (ponesimod) receives positive CHMP opinion for the treatment of adults with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features	(press release)
	CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) accepted for accelerated assessment in Europe for the treatment of patients with heavily pretreated multiple myeloma	(press release)

¹ Subsequent to the quarter

FULL-YEAR 2021 GUIDANCE:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

(\$ in Billions, except EPS)	January 2021	April 2021
Adjusted Operational Sales ^{1,2}		
Change vs. Prior Year	8.0% - 9.5%	8.7% - 9.9%
Operational Sales ²	\$88.8B - \$90.0B	\$89.3B - \$90.3B
Change vs. Prior Year	7.5% - 9.0%	8.2% - 9.4%
Estimated Reported Sales ³	\$90.5B - \$91.7B	\$90.6B - \$91.6B
Change vs. Prior Year	9.5% - 11.0%	9.7% - 10.9%
Adjusted Operational EPS (Diluted) ^{2,4}	\$9.25 - \$9.45	\$9.30 - \$9.45
Change vs. Prior Year	15.2% - 17.7%	15.8% - 17.7%
Adjusted EPS (Diluted) ^{3,4}	\$9.40 - \$9.60	\$9.42 - \$9.57
Change vs. Prior Year	17.1% - 19.6%	17.3% - 19.2%

¹ [Non-GAAP financial measure](#); excludes the net impact of acquisitions and divestitures

² [Non-GAAP financial measure](#); excludes the impact of translational currency

³ Calculated using Euro Average Rate: January 2021 = \$1.21 and April 2021 = \$1.19 (Illustrative purposes only)

⁴ [Non-GAAP financial measure](#); excludes intangible amortization expense and special items

Other modeling considerations will be provided on the [webcast](#).

WEBCAST INFORMATION:

Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the [Johnson & Johnson website](#). A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at [events-and-presentations](#).

ABOUT JOHNSON & JOHNSON:

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

NON-GAAP FINANCIAL MEASURES:

*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at [quarterly-results](#).

Copies of the financial schedules accompanying this earnings release are available on the company's website at [quarterly-results](#). These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a [pharmaceutical pipeline](#) of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investors section of the company's website at [quarterly-results](#).

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Press Contacts:

Christina Chan
(732) 524-6297

Courtney Dugan
(347) 452-1061

Investor Contacts:

Christopher DelOrefice
(732) 524-2955

Sarah Wood
(732) 524-2617

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)

FIRST QUARTER

				Percent Change	
	2021	2020	Total	Operations	Currency
Sales to customers by segment of business					
Consumer Health					
U.S.	\$ 1,611	1,740	(7.4) %	(7.4)	-
International	1,932	1,885	2.5	0.5	2.0
	3,543	3,625	(2.3)	(3.3)	1.0
Pharmaceutical					
U.S.	6,446	6,061	6.4	6.4	-
International	5,753	5,073	13.4	7.9	5.5
	12,199	11,134	9.6	7.1	2.5
Medical Devices					
U.S.	3,054	2,898	5.4	5.4	-
International	3,525	3,034	16.2	10.5	5.7
	6,579	5,932	10.9	8.0	2.9
U.S.	11,111	10,699	3.9	3.9	-
International	11,210	9,992	12.2	7.3	4.9
Worldwide	\$ 22,321	20,691	7.9 %	5.5	2.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries**Supplementary Sales Data**

(Unaudited; Dollars in Millions)

FIRST QUARTER

	2021	2020	Total	Percent Change	
				Operations	Currency
Sales to customers by geographic area					
U.S.	\$ 11,111	10,699	3.9 %	3.9	-
Europe	5,414	4,827	12.1	4.7	7.4
Western Hemisphere excluding U.S.	1,424	1,502	(5.1)	0.0	(5.1)
Asia-Pacific, Africa	4,372	3,663	19.4	13.7	5.7
International	11,210	9,992	12.2	7.3	4.9
Worldwide	\$ 22,321	20,691	7.9 %	5.5	2.4

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

FIRST QUARTER

	2021		2020		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 22,321	100.0	\$ 20,691	100.0	7.9
Cost of products sold	7,063	31.7	7,062	34.1	0.0
Gross Profit	15,258	68.3	13,629	65.9	12.0
Selling, marketing and administrative expenses	5,432	24.3	5,203	25.1	4.4
Research and development expense	3,178	14.2	2,580	12.5	23.2
Interest (income) expense, net	48	0.2	(42)	(0.2)	
Other (income) expense, net	(882)	(3.9)	(679)	(3.3)	
Restructuring	53	0.2	58	0.3	
Earnings before provision for taxes on income	7,429	33.3	6,509	31.5	14.1
Provision for taxes on income	1,232	5.5	713	3.5	72.8
Net earnings	6,197	27.8	5,796	28.0	6.9
Net earnings per share (Diluted)	\$ 2.32		\$ 2.17		6.9
Average shares outstanding (Diluted)	2,672.7		2,671.0		
Effective tax rate	16.6 %		11.0 %		
Adjusted earnings before provision for taxes and net earnings (1)					
Earnings before provision for taxes on income	\$ 8,291	37.1	\$ 7,244	35.0	14.5
Net earnings	\$ 6,924	31.0	\$ 6,154	29.7	12.5
Net earnings per share (Diluted)	\$ 2.59		\$ 2.30		12.6
Effective tax rate	16.5 %		15.0 %		

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	First Quarter	
(Dollars in Millions Except Per Share Data)	2021	2020
Net Earnings, after tax- as reported	\$6,197	\$5,796
<i>Pre-tax Adjustments</i>		
Intangible Asset Amortization expense	1,215	1,118
Litigation expense	-	120
Restructuring related	104	118
Acquisition, integration and divestiture related ¹	(538)	(962)
Unrealized (gains)/losses on securities	35	327
Medical Device Regulation	46	14
<i>Tax Adjustments</i>		
Tax impact on special item adjustments ²	(113)	(267)
Tax legislation and other tax related	(22)	(110)
Adjusted Net Earnings, after tax	\$6,924	\$6,154
Average shares outstanding (Diluted)	2,672.7	2,671.0
Adjusted net earnings per share (Diluted)	\$2.59	\$2.30
Operational adjusted net earnings per share (Diluted)	\$2.49	

Notes:

¹ Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2 Pharmaceutical brands outside of the U.S. The first quarter of 2020 primarily includes a \$983M Contingent Consideration reversal related to the timing of certain developmental milestones associated with the Auris Health acquisition.

² The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Adjusted Operational Sales Growth
FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL

	Segments			
	Consumer Health	Pharmaceutical	Medical Devices	Total
WW As Reported	(2.3)%	9.6%	10.9%	7.9%
U.S.	(7.4)%	6.4%	5.4%	3.9%
International	2.5%	13.4%	16.2%	12.2%
WW Currency	1.0	2.5	2.9	2.4
U.S.	-	-	-	-
International	2.0	5.5	5.7	4.9
WW Operational	(3.3)%	7.1%	8.0%	5.5%
U.S.	(7.4)%	6.4%	5.4%	3.9%
International	0.5%	7.9%	10.5%	7.3%
General Surgery				
Advanced Sterilization Products			0.6	0.2
U.S.			0.0	0.0
International			1.2	0.4
All Other Acquisitions and Divestitures	0.4	0.3	0.1	0.3
U.S.	0.5	(0.2)	0.2	0.0
International	0.4	0.9	0.0	0.5
WW Adjusted Operational	(2.9)%	7.4%	8.8%	6.0%
U.S.	(6.9)%	6.2%	5.6%	3.9%
International	0.9%	8.8%	11.8%	8.2%

Note: Percentages are based on actual, non-rounded figures and may not sum



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ⁽²⁾					
<u>OTC</u>					
US	\$ 599	689	-13.0%	-13.0%	-
Intl	575	659	-12.8%	-16.6%	3.8%
WW	1,175	1,348	-12.9%	-14.8%	1.9%
<u>SKIN HEALTH / BEAUTY</u>					
US	634	659	-3.9%	-3.9%	-
Intl	529	458	15.7%	12.3%	3.4%
WW	1,163	1,117	4.1%	2.8%	1.3%
<u>ORAL CARE</u>					
US	163	176	-7.2%	-7.2%	-
Intl	254	219	16.0%	13.9%	2.1%
WW	417	395	5.7%	4.5%	1.2%
<u>BABY CARE</u>					
US	96	92	4.2%	4.2%	-
Intl	293	269	8.9%	11.3%	-2.4%
WW	389	361	7.7%	9.5%	-1.8%
<u>WOMEN'S HEALTH</u>					
US	3	4	-25.8%	-25.8%	-
Intl	219	228	-3.9%	-2.2%	-1.7%
WW	222	232	-4.3%	-2.6%	-1.7%
<u>WOUND CARE / OTHER</u>					
US	115	119	-3.0%	-3.0%	-
Intl	61	52	17.6%	14.2%	3.4%
WW	177	171	3.3%	2.2%	1.1%
<u>TOTAL CONSUMER HEALTH</u>					
US	1,611	1,740	-7.4%	-7.4%	-
Intl	1,932	1,885	2.5%	0.5%	2.0%
WW	\$ 3,543	3,625	-2.3%	-3.3%	1.0%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT ^(2,3)

IMMUNOLOGY

	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 2,413	2,410	0.1%	0.1%	-
Intl	1,501	1,228	22.3%	15.9%	6.4%
WW	3,914	3,638	7.6%	5.5%	2.1%

REMICADE

US	489	625	-21.7%	-21.7%	-
US Exports ⁽⁴⁾	57	110	-48.4%	-48.4%	-
Intl	232	256	-9.4%	-12.1%	2.7%
WW	777	990	-21.5%	-22.2%	0.7%

SIMPONI / SIMPONI ARIA

US	255	272	-5.9%	-5.9%	-
Intl	307	258	18.9%	13.8%	5.1%
WW	562	529	6.2%	3.7%	2.5%

STELARA

US	1,331	1,217	9.4%	9.4%	-
Intl	817	603	35.6%	27.6%	8.0%
WW	2,148	1,819	18.1%	15.4%	2.7%

TREMFYA

US	274	187	46.3%	46.3%	-
Intl	143	109	32.0%	23.1%	8.9%
WW	418	296	41.0%	37.8%	3.2%

OTHER IMMUNOLOGY

US	7	-	*	*	-
Intl	2	3	-38.4%	-36.3%	-2.1%
WW	8	3	*	*	*

INFECTIOUS DISEASES

US	512	436	17.4%	17.4%	-
Intl	494	483	2.3%	-2.2%	4.5%
WW	1,007	920	9.5%	7.1%	2.4%

COVID-19 VACCINE

US	100	-	*	*	-
Intl	-	-	-	-	-
WW	100	-	*	*	-

EDURANT / rilpivirine

US	10	12	-12.3%	-12.3%	-
Intl	233	212	9.8%	0.9%	8.9%
WW	243	224	8.6%	0.2%	8.4%

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

US	380	396	-3.8%	-3.8%	-
Intl	166	184	-9.9%	-10.4%	0.5%
WW	546	579	-5.8%	-5.9%	0.1%

OTHER INFECTIOUS DISEASES

US	21	29	-27.0%	-27.0%	-
Intl	96	87	9.7%	7.4%	2.3%
WW	117	116	0.6%	-1.2%	1.8%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2021</u>	<u>2020</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational</u> ⁽¹⁾	<u>Currency</u>
<u>NEUROSCIENCE</u>					
US	771	748	3.2%	3.2%	-
Intl	949	910	4.3%	0.4%	3.9%
WW	<u>1,721</u>	<u>1,658</u>	3.8%	1.6%	2.2%
<u>CONCERTA / Methylphenidate</u>					
US	47	52	-9.6%	-9.6%	-
Intl	123	118	4.5%	-0.4%	4.9%
WW	<u>171</u>	<u>171</u>	0.2%	-3.2%	3.4%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>					
US	589	544	8.3%	8.3%	-
Intl	376	339	11.0%	4.5%	6.5%
WW	<u>965</u>	<u>883</u>	9.4%	6.9%	2.5%
<u>RISPERDAL CONSTA</u>					
US	67	76	-11.8%	-11.8%	-
Intl	89	94	-4.8%	-8.8%	4.0%
WW	<u>157</u>	<u>170</u>	-7.9%	-10.1%	2.2%
<u>OTHER NEUROSCIENCE</u>					
US	67	75	-9.8%	-9.8%	-
Intl	361	360	0.2%	-0.9%	1.1%
WW	<u>428</u>	<u>435</u>	-1.5%	-2.5%	1.0%
<u>ONCOLOGY</u>					
US	1,377	1,175	17.2%	17.2%	-
Intl	2,193	1,839	19.3%	12.9%	6.4%
WW	<u>3,570</u>	<u>3,013</u>	18.5%	14.6%	3.9%
<u>DARZALEX</u>					
US	691	463	49.2%	49.2%	-
Intl	674	474	42.2%	35.3%	6.9%
WW	<u>1,365</u>	<u>937</u>	45.6%	42.2%	3.4%
<u>ERLEADA</u>					
US	171	119	44.0%	44.0%	-
Intl	90	24	*	*	*
WW	<u>261</u>	<u>143</u>	82.8%	79.7%	3.1%
<u>IMBRUVICA</u>					
US	444	432	2.8%	2.8%	-
Intl	680	599	13.5%	7.6%	5.9%
WW	<u>1,125</u>	<u>1,031</u>	9.0%	5.6%	3.4%
<u>ZYTIGA / abiraterone acetate</u>					
US	50	139	-64.2%	-64.2%	-
Intl	588	552	6.6%	0.0%	6.6%
WW	<u>638</u>	<u>690</u>	-7.6%	-12.9%	5.3%
<u>OTHER ONCOLOGY</u> ⁽⁵⁾					
US	21	22	-5.1%	-5.1%	-
Intl	161	190	-15.3%	-19.3%	4.0%
WW	<u>182</u>	<u>212</u>	-14.2%	-17.9%	3.7%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	<u>2021</u>	<u>2020</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational</u> ⁽¹⁾	<u>Currency</u>
<u>PULMONARY HYPERTENSION</u>					
US	573	486	18.0%	18.0%	-
Intl	288	260	10.8%	5.6%	5.2%
WW	<u>861</u>	<u>745</u>	15.5%	13.7%	1.8%
<u>OPSUMIT</u>					
US	272	229	18.5%	18.5%	-
Intl	179	160	11.5%	6.3%	5.2%
WW	<u>450</u>	<u>389</u>	15.6%	13.5%	2.1%
<u>UPTRAVI</u>					
US	259	212	21.9%	21.9%	-
Intl	46	38	23.0%	15.7%	7.3%
WW	<u>305</u>	<u>250</u>	22.0%	20.9%	1.1%
<u>OTHER PULMONARY HYPERTENSION</u>					
US	42	44	-3.5%	-3.5%	-
Intl	63	62	1.4%	-2.1%	3.5%
WW	<u>105</u>	<u>106</u>	-0.6%	-2.7%	2.1%
<u>CARDIOVASCULAR / METABOLISM / OTHER</u>					
US	799	806	-0.9%	-0.9%	-
Intl	328	354	-7.2%	-11.3%	4.1%
WW	<u>1,127</u>	<u>1,160</u>	-2.8%	-4.1%	1.3%
<u>XARELTO</u>					
US	589	527	11.7%	11.7%	-
Intl	-	-	-	-	-
WW	<u>589</u>	<u>527</u>	11.7%	11.7%	-
<u>INVOKANA / INVOKAMET</u>					
US	87	117	-26.1%	-26.1%	-
Intl	63	58	9.2%	4.2%	5.0%
WW	<u>150</u>	<u>175</u>	-14.4%	-16.1%	1.7%
<u>PROCRIT / EPREX</u>					
US	62	76	-18.3%	-18.3%	-
Intl	64	79	-18.1%	-22.2%	4.1%
WW	<u>127</u>	<u>155</u>	-18.2%	-20.3%	2.1%
<u>OTHER</u>					
US	60	85	-28.8%	-28.8%	-
Intl	201	217	-7.7%	-11.5%	3.8%
WW	<u>261</u>	<u>302</u>	-13.6%	-16.4%	2.8%
<u>TOTAL PHARMACEUTICAL</u>					
US	6,446	6,061	6.4%	6.4%	-
Intl	5,753	5,073	13.4%	7.9%	5.5%
WW	<u>\$ 12,199</u>	<u>11,134</u>	9.6%	7.1%	2.5%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

MEDICAL DEVICES SEGMENT ⁽²⁾

INTERVENTIONAL SOLUTIONS

	<u>2021</u>	<u>2020</u>	<u>% Change</u>		
			<u>Reported</u>	<u>Operational</u> ⁽¹⁾	<u>Currency</u>
US	\$ 434	365	19.0%	19.0%	-
Intl	514	362	42.0%	34.0%	8.0%
WW	<u>949</u>	<u>727</u>	30.4%	26.4%	4.0%

ORTHOPAEDICS

US	1,249	1,250	-0.1%	-0.1%	-
Intl	864	788	9.7%	3.1%	6.6%
WW	<u>2,113</u>	<u>2,038</u>	3.7%	1.2%	2.5%

HIPS

US	210	206	2.4%	2.4%	-
Intl	146	132	11.2%	4.5%	6.7%
WW	<u>357</u>	<u>337</u>	5.8%	3.2%	2.6%

KNEES

US	185	214	-13.5%	-13.5%	-
Intl	132	130	2.0%	-4.1%	6.1%
WW	<u>317</u>	<u>343</u>	-7.6%	-9.9%	2.3%

TRAUMA

US	450	407	10.7%	10.7%	-
Intl	282	247	14.4%	7.7%	6.7%
WW	<u>733</u>	<u>654</u>	12.1%	9.5%	2.6%

SPINE, SPORTS & OTHER

US	403	423	-4.8%	-4.8%	-
Intl	303	280	8.4%	1.7%	6.7%
WW	<u>706</u>	<u>703</u>	0.4%	-2.2%	2.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2021	2020	% Change		
			Reported	Operational ⁽¹⁾	Currency
<u>SURGERY</u>					
US	898	844	6.5%	6.5%	-
Intl	1,474	1,257	17.3%	11.7%	5.6%
WW	<u>2,372</u>	<u>2,100</u>	12.9%	9.6%	3.3%
<u>ADVANCED</u>					
US	405	381	6.5%	6.5%	-
Intl	713	567	25.7%	19.5%	6.2%
WW	<u>1,118</u>	<u>948</u>	18.0%	14.3%	3.7%
<u>GENERAL</u>					
US	493	463	6.5%	6.5%	-
Intl	761	690	10.3%	5.3%	5.0%
WW	<u>1,254</u>	<u>1,153</u>	8.8%	5.8%	3.0%
<u>VISION</u>					
US	472	439	7.4%	7.4%	-
Intl	673	628	7.3%	3.9%	3.4%
WW	<u>1,145</u>	<u>1,067</u>	7.3%	5.4%	1.9%
<u>CONTACT LENSES / OTHER</u>					
US	371	346	7.2%	7.2%	-
Intl	486	467	4.0%	0.9%	3.1%
WW	<u>857</u>	<u>814</u>	5.3%	3.5%	1.8%
<u>SURGICAL</u>					
US	101	93	8.2%	8.2%	-
Intl	187	160	17.0%	12.9%	4.1%
WW	<u>288</u>	<u>253</u>	13.7%	11.2%	2.5%
<u>TOTAL MEDICAL DEVICES</u>					
US	3,054	2,898	5.4%	5.4%	-
Intl	3,525	3,034	16.2%	10.5%	5.7%
WW	<u>\$ 6,579</u>	<u>5,932</u>	10.9%	8.0%	2.9%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

(4) Reported as U.S. sales

(5) Refer to supplemental schedule

Supplemental Sales Information
(Dollars in Millions)

Prior quarter amounts have been reclassified to conform to current quarter product disclosure

	2019	2020				2020
	<u>Full Year</u>	<u>Q1</u>	<u>Q2</u>	<u>Q3</u>	<u>Q4</u>	<u>Full Year</u>
<u>PHARMACEUTICAL SEGMENT</u> ⁽¹⁾						
<u>Oncology</u>						
<u>OTHER ONCOLOGY</u> ⁽²⁾						
US	70	22	20	21	20	83
Intl	<u>1,087</u>	<u>190</u>	<u>185</u>	<u>181</u>	<u>183</u>	<u>738</u>
WW	<u>1,158</u>	<u>212</u>	<u>204</u>	<u>203</u>	<u>202</u>	<u>821</u>

Note: Columns and rows within tables may not add due to rounding.

(1) Unaudited

(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately